首页> 外文期刊>PLoS One >Comparison of the pain-reducing effects of EMLA cream and of lidocaine tape during arteriovenous fistula puncture in patients undergoing hemodialysis: A multi-center, open-label, randomized crossover trial
【24h】

Comparison of the pain-reducing effects of EMLA cream and of lidocaine tape during arteriovenous fistula puncture in patients undergoing hemodialysis: A multi-center, open-label, randomized crossover trial

机译:血液透析患者中动胞瘘疼痛的疼痛降低效应的比较:多中心,开放标签,随机交叉试验

获取原文
           

摘要

Arteriovenous fistula puncture pain is a serious problem for patients undergoing dialysis and a good indication for topical anesthetics. No previous study has compared lidocaine/prilocaine cream (EMLA) with lidocaine tape for pain relief during arteriovenous fistula puncture in patients undergoing maintenance hemodialysis. To this end, we conducted a multicenter randomized crossover study including 66 patients (mean age, 65.8 years; males, 57.6%) undergoing maintenance hemodialysis thrice/week. Subjects were assigned to Sequence EL (EMLA administration followed by lidocaine, with 1-week wash-out) or Sequence LE (reverse administration, first lidocaine then EMLA). All subjects completed the study. At each puncture site, 1 g EMLA (25 mg lidocaine + 25 mg prilocaine) or one sheet of lidocaine tape (18 mg lidocaine) was applied 1 h or 30 min prior to arteriovenous fistula puncture, respectively. The primary endpoint was puncture pain relief, which was measured using a 100-mm visual analog scale. The secondary endpoints included quality of life, which was measured by SF-36, and safety. EMLA produced a 10.1-mm greater visual analog scale improvement than lidocaine tape (P = 0.00001). However, there was no statistically significant difference in the quality of life between the two groups, and no significant carryover/period effect was observed in any analysis. Further, no drug-related adverse events were observed. Taken together, these results suggest that EMLA cream is superior to lidocaine tape for the relief of arteriovenous fistula puncture pain in patients undergoing maintenance hemodialysis. Trial registration: University Hospital Medical Information Network Clinical Trials Registry (UMIN000027885).
机译:动脉瘘穿刺疼痛是透析患者的严重问题,以及局部麻醉剂的良好迹象。没有先前的研究将Lidocaine / prilocaine奶油(Emla)与Lidocaine胶带进行Lidocaine胶带,用于在进行血液透析的患者中动脉瘘穿刺期间疼痛缓解。为此,我们进行了一项多中心随机交叉研究,包括66名患者(平均年龄,65.8岁;男性,57.6%)接受血液透析/周进行维持血液透析。将受试者分配给序列EL(Emla施用,然后用Lidocaine,用1周洗涤)或序列Le(反向给药,第一个Lidocaine然后Emla)。所有受试者都完成了这项研究。在每个穿刺部位,在动静脉瘘穿刺之前,1g Emla(25mg lidocaine + 25mg prilocaine)或一片利多卡因胶带(18mg lidocaine)施用1小时或30分钟。主要终点是穿刺疼痛缓解,其使用100mm视觉模拟量表测量。辅助端点包括使用SF-36测量的寿命的质量和安全性。 EMLA产生了比Lidocaine胶带的10.1毫米更大的视觉模拟刻度改进(P = 0.00001)。然而,两组之间的寿命质量没有统计学上显着差异,并且在任何分析中都没有观察到显着的残留/周期效应。此外,没有观察到药物相关的不良事件。这些结果表明,Emla霜优于Lidocaine胶带,用于缓解血液透析患者的动静脉瘘穿刺疼痛。审判登记:大学医院医疗信息网络临床试验登记册(UMIN000027885)。

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号